Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT.

• Abstract: PURPOSE: The objective of this study was to investigate the rate of progression of nigrostriatal dopaminergic loss in subjects with dementia with Lewy bodies (DLB), Parkinson's disease (PD) and PD with dementia (PDD) using serial 123I-FP-CIT SPECT imaging. We hypothesised that striatal rates of decline in patients would be greater than in controls, and that DLB and PDD would show similar rates, reflecting the similarity in neurobiological mechanisms of dopaminergic loss between the two disorders. METHODS: We studied 20 patients with DLB, 20 with PD, 15 with PDD and 22 healthy age-matched controls. Semi-automated region of interest (ROI) analysis was performed on both baseline and repeat scans for each subject and mean striatal uptake ratios (caudate, anterior and posterior putamen) were calculated. RESULTS: Rates of decline in striatal binding between groups were assessed using ANCOVA. Significant differences between patients and controls were observed in caudate (DLB, PD, PDD, p< or =0.01), anterior putamen (DLB, PDD, p< or =0.05; PD, p=0.07) and posterior putamen (DLB, PD, PDD, p<0.006). Rates of decline were similar between DLB, PD and PDD. CONCLUSION: In conclusion, this is the first study to show that significant progressive dopaminergic loss occurs in DLB and PDD using serial 123I-FP-CIT SPECT. Dementia severity and motor impairment were correlated with decline, suggesting that dopaminergic loss may play an important role in cognitive as well as motor features.
• Authors: Sean J Colloby, E David Williams, David J Burn, Jim J Lloyd, Ian G McKeith, John T O'Brien (Affiliation: Institute for Ageing and Health, Wolfson Research Centre, Newcastle General Hospital, Newcastle University, Westgate Road, Newcastle upon Tyne, NE4 6BE, UK. s.j.colloby at ncl.ac.uk)
• Journal: European journal of nuclear medicine and molecular imaging (Eur J Nucl Med Mol Imaging) Vol. 32 Issue 10 Pg. 1176-85 (Oct 2005) ISSN: 1619-7070 [Print] Germany
• PMID: 15931516 (Publication Type: Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Radiopharmaceuticals
• Tropanes
• 2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane

Topics

• Aged
• Corpus Striatum (metabolism, radionuclide imaging)
• Dementia (complications, metabolism, radionuclide imaging)
• Disease Progression
• Dopamine (metabolism)
• Female
• Humans
• Lewy Body Disease (metabolism, radionuclide imaging)
• Male
• Parkinson Disease (complications, metabolism, radionuclide imaging)
• Radiopharmaceuticals (diagnostic use, pharmacokinetics)
• Severity of Illness Index
• Tomography, Emission-Computed, Single-Photon (methods)
• Tropanes (diagnostic use, pharmacokinetics)